Zymeworks Return on Tangible Equity 2016-2022 | ZYME

Current and historical return on tangible equity values for Zymeworks (ZYME) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Zymeworks Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.24B $0.27B -90.18%
2021-12-31 $-0.21B $0.23B -73.20%
2021-09-30 $-0.21B $0.26B -64.05%
2021-06-30 $-0.22B $0.31B -60.79%
2021-03-31 $-0.20B $0.36B -47.56%
2020-12-31 $-0.18B $0.39B -40.58%
2020-09-30 $-0.22B $0.41B -53.12%
2020-06-30 $-0.17B $0.47B -45.99%
2020-03-31 $-0.16B $0.51B -48.14%
2019-12-31 $-0.15B $0.23B -58.12%
2019-09-30 $-0.06B $0.29B -27.32%
2019-06-30 $-0.05B $0.32B -26.47%
2019-03-31 $-0.03B $0.16B -18.38%
2018-12-31 $-0.04B $0.17B -25.61%
2018-09-30 $-0.01B $0.16B -10.10%
2018-06-30 $-0.01B $0.17B -9.30%
2018-03-31 $-0.02B $0.08B -17.60%
2017-12-31 $-0.01B $0.10B -13.51%
2017-09-30 $-0.05B $0.07B -87.45%
2017-06-30 $-0.05B $0.09B -112.99%
2017-03-31 $-0.05B $0.04B -200.00%
2016-12-31 $-0.03B $0.06B -240.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.320B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00